Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 17, 2006

View Archived Issues

Novel treatment strategies for cancer covered in recent patent literature

Recent patents describe new analgesic agents

Recent patents describe novel agents for anxiety, depression, psychosis etc.

Recent Universitaetsklinikum Muenster patent discloses novel diagnostic agents

Amoxicillin PULSYS demonstrates bacterial eradication in adults and adolescents

Visual acuity stabilization eight weeks after a single dose of Sirna-027

RabiCide to enter preclinical testing for rabies by 2007

Acrux and Population Council amend transdermal contraceptive agreement

Novartis, Schering-Plough to develop once-daily therapy for asthma and COPD

Additional information for Herceptin sBLA deemed major amendment

Gilead completes acquisition of Corus Pharma

Genzyme seeks to expand European label of Synvisc

Pharmexa discontinues phase II study of HER-2 Protein AutoVac

Approvable letter for eprodisate for AA amyloidosis

Delta opioid agonist provides effective analgesia in preclinical bone cancer pain

Jak2 validated as a therapeutic target for CML

Phase IIa asthma study of LAB CGRP completes enrollment

Nastech studies PYY3-36 nasal spray in dose-ranging obesity study

Depomed completes phase I study with GERD compound

DG-051 enters phase I for prevention of heart attack

Phase II trial studies Iomai's vaccine patch for travelers' diarrhea

Targeting 5-HT2A receptor-mediated nociception relieves painful symptoms following tissue injury

PI3Kdelta inhibition with IC-87114 has shown benefit in a murine model of allergic asthma

Galvus filed for European approval in type 2 diabetes

Soltamox launched in the U.S.

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 31, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 2, 2026.
AND-017 increases RBC and hemoglobin in sickle cell disease
BioWorld Science
Sickle cell disease (SCD) is an inherited hemoglobinopathy caused by a mutation in the gene encoding β-globin that results in hemoglobin S polymerization, red...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...